Array has a strong history of collaborating with partners who share our commitment to discover, develop and commercialize small molecule drugs that can make a real difference.
Array has exclusive rights to encorafenib and binimetinib in the U.S. and Canada. We have granted:
Ono Pharmaceutical exclusive rights to commercialize both products in Japan and South Korea;
Medison exclusive rights to commercialize both products in Israel;
and Pierre Fabre exclusive rights to commercialize both products in all other countries, including those in Europe, Asia and Latin America (excluding Japan and South Korea).
Pierre Fabre is supporting select clinical trials of encorafenib and binimetinib, including the BEACON CRC trial.
Ono is supporting select clinical trials of encorafenib and binimetinib, including the BEACON CRC trial.
Merck KGaA, Darmstadt, Germany, will supply cetuximab to all sites for the Phase 3 BEACON CRC trial.
In 2014, we granted Cascadian Therapeutics an exclusive license to develop, manufacture and commercialize tucatinib, an orally active, reversible and selective small molecule HER2 inhibitor. In 2018, Seattle Genetics acquired Cascadian Therapeutics and is responsible for the tucatinib program.
Immuno-oncology Combination Collaborations
In 2017, we initiated a collaboration with Bristol-Myers Squibb for a clinical trial of binimetinib in combination with nivolumab (anti–PD-1 therapy), with and without ipilimumab (CTLA-4 antibody), in patients with advanced metastatic microsatellite stable (MSS) CRC and the presence of a RAS mutation who have received one or two prior regimens.
In 2017, we initiated a collaboration with Merck for a clinical trial of binimetinib in combination with pembrolizumab (anti–PD-1 therapy), with and without FOLFOX or FOLFIRI (chemotherapy), in first- or second-line patients with colorectal cancer whose tumors are not microsatellite instability-high (MSI-H).
In 2017, we initiated a collaboration with Pfizer for a clinical trial to explore several novel anticancer combinations, including binimetinib, avelumab (anti–PD-L1 therapy) and talazoparib (PARP inhibitor) across various tumor types. Initially, the focus will be in non-small cell lung cancer (NSCLC) and pancreatic cancer, with additional indications being explored at a later stage.
Discovery and preclinical partnerships
We are working with numerous partners to design, create and optimize drug candidates. These efforts span a broad range of therapeutic areas, including autoimmune disorders, oncology and pain.
BECOME A COLLABORATOR
The challenges facing the pharmaceutical industry make the choice of a strategic discovery partner more important than ever.
We continue to seek partners who are searching for a Research & Discovery team that brings innovative science, best-in-class processes and a sense of urgency to tackling significant unmet medical needs.